Stock ABCL ABCELLERA BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.63 USD -6.92% Intraday chart for AbCellera Biologics Inc. -7.16% -36.43%
Mar. 11 AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases MT
Mar. 11 AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ABCELLERA BIOLOGICS INC. Stock AbCellera Biologics Inc.
-36.43% 1.06B -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 42.59B
B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 40.65B
B-
LONZA GROUP AG Stock Lonza Group AG
+47.58% 40.57B
A
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 26.77B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 24.81B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.17B
B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 11.7B
C+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.05B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.1B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ABCL Stock
  4. Ratings AbCellera Biologics Inc.